濮阳东方妇科口碑评价高(濮阳东方妇科咨询医生在线) (今日更新中)

SAN DIEGO (KGTV) -- Caltrans plans to close a portion of eastbound State Route 56 overnight Thursday.According to the agency, all eastbound lanes of SR-56 at Camino Del Sur as well as the Camino Del Sur on-ramp will close Thursday from 12:01 a.m. to 4 a.m.The closure will take place so crews can work on the Carmel Road overcrossing. The work is part of a county-wide project to install self-reflecting signs.CHECK TRAFFIC CONDITIONSAccording to Caltrans, the new signs will enhance nighttime visibility and will replace signs that require light fixtures. 569

SAN DIEGO (KGTV) – County leaders are continuing to urge San Diegans that 2020 is not the year to skip the flu shot as we head into colder months amid a nearly year-long pandemic.On Wednesday, the fourth of six flu vaccine clinics was held by San Diego County’s Health and Human Services in Logan Heights. All hands were on deck with nurses from across the county, as more people are heading to the free clinics to get their flu shot this season."This is a year to be vigilant of protecting yourself from influenza and getting a vaccine, so we don't run into a situation where people are not only getting COVID, but getting influenza, and clogging our medical response system," said Thomas Zurek, public health nurse manager with the county.Zurek said while we can't control the spread of COVID-19 with a vaccine, we can when it comes to the spread of influenza, which hits hard during cold months when more people are indoors.Zurek added he hopes the free clinics will help keep people out of hospitals this season so staff can focus patients affected by COVID-19."Our numbers have been above what we're normally than seeing this time of year, which is great," Zurek said.The county will hold two more vaccine clinics Thursday and next Tuesday:Thursday, Oct. 29, at East Public Health Center, 367 N. Magnolia Avenue, El CajonTuesday, Nov. 3, at North Inland Public Health Center, 640 W. Mission Ave #2, Escondido 1421

SAN DIEGO (KGTV) — As states continue to count votes, one thing is clear: the pre-election polls were off again.Pollsters underestimated support for President Donald Trump by a wider margin than they did in 2016, prompting a number of theories about what went wrong and why changes adopted after the 2016 election proved ineffective.Heading into Election Day 2020, candidate Joe Biden led Trump nationally by an average of 8.4%, according to FiveThirtyEight’s polling average. We won’t know the final margin until all the votes are counted, but it looks like Trump’s support was underestimated by about 3.5%.That’s wider than the national popular vote miss in 2016, when the polls underestimated Trump’s support by 1.1%.“Polling emerged from 2016 with a black eye. This is fair to say a second black eye in 2020,” said Jay Leve of polling firm SurveyUSA.Leve said the industry thought it had corrected its 2016 mistakes. Polling in the 2018 midterms was very accurate.In 2020, pollsters made sure to weigh for education level and include enough non-college-educated white voters to try to capture a representative sample of the electorate.But state polls show it didn’t work. In Ohio, there was a nearly 8-point miss. In Wisconsin, there was a nearly 10-point miss. In Florida, the polls missed by 5 points and incorrectly showed Biden in the lead.“While pollsters attempted to correct for the mistakes that they made in 2016, President Trump was busy hammering home a narrative that, number one, the media is the enemy of the people. And number two, polls are fake polls,” Leve said.Leve thinks that skepticism and distrust caused Trump supporters to ignore pollsters at a higher rate, causing them to be underrepresented in samples.San Diego State political scientist Dr. Stephen Goggin says there are other theories as well.“Between mail-in balloting, the pandemic, between all the early voting and all the confusion it creates, it’s possible some of that played a role in creating the error we saw this time,” he said.Goggin said the pandemic may have made the models used to predict voter turnout less accurate this cycle. Many surveys heading into the election showed an unusual trend: Biden was polling better among so-called “likely voters” than among registered voters overall. Typically Republicans hold an edge among likely voters, Nate Cohn of the New York Times noted.There’s also some early data suggesting once the pandemic hit, Democrats started responding to surveys more frequently, something that could have shifted the poll numbers.There may have also been issues surveying certain demographic groups. Pre-election polls showed Biden chipping away at Trump’s lead with seniors compared to 2016, but Biden actually did worse than Clinton with that demographic in certain key states. Trump’s support among Hispanic voters in Florida also surprised pollsters. If exit polling data shows that trend continued in other states, it might explain about one-quarter of this year’s polling error, according to the New York Times.“Many of these errors are fixable when they find out what went wrong and you can still get high-quality samples,” Goggin said.Pollsters are planning to do detailed autopsies on the election once they have final turnout data and results by precinct. Polling firms will eventually post detailed data from their results to the Roper Center for more finely tuned analysis.ABC 10News used SurveyUSA this election cycle to poll 11 state and local races. The final polls accurately predicted the winner in all 11 races, although the margins weren’t perfect.The ABC 10News/Union-Tribune scientific polls actually overestimated Trump’s support in California by about 4 points, relative to vote totals as of November 12. 3757

SAN DIEGO (KGTV) — As the world waits for a vaccine against the coronavirus, two San Diego biotechs are teaming up to develop a nasal spray using designer antibodies cloned from COVID-19 survivors.About 70 companies worldwide are working on therapies for COVID-19 using cloned antibodies, according to an estimate by the International AIDS Vaccine Initiative. A few of these treatments, known officially as monoclonal antibody therapies, have advanced to clinical trials.Most require an injection, but San Diego-based Diomics and its partner Active Motif, based in Carlsbad, are developing a once-a-day spray that could be easily self-administered.Early research suggests the coronavirus primarily enters the body through the nose. The spray, called Dioguard, is designed to coat the lining of the nasal cavity with cloned antibodies that are held in place for 24 hours or more using a proprietary polymer material developed by Diomics.Diomics CEO Anthony Zolezzi said he believes the spray “holds the key to allowing many aspects of life to resume until the day comes when there’s an effective vaccine in widespread use.”Diomics is also developing two tests for COVID-19 antibodies using its polymer beads, including a device that looks like a nicotine patch that is designed to monitor for infections for a week or more.RELATED: How a dot on your forearm could be the future sign of COVID immunityActive Motif is providing the cloned antibodies for the nasal spray. With a lab in Shanghai and other relationships in China, the Carlsbad company was able to clone antibodies from 11 Chinese survivors in February, before the World Health Organization declared a pandemic.When the company started the cloning project, they thought the virus would probably disappear in three to six months, said Active Motif CEO Ted DeFrank. “Then people started realizing, no this is going to be with us for a while.”The plasma from the 11 Chinese patients contained thousands of antibodies, and scientists with Active Motif set about selecting the one that was most effective, dubbed 414-1. The company says it can neutralize SARS-CoV-2 virus particles with 98 percent effectiveness.Monoclonal antibodies have some similarities to convalescent plasma, which is a complex cocktail of antibodies and other immune molecules drawn from the blood of recovered patients. One of the key differences is that cloned antibodies can be mass produced in a lab.Cloned antibodies have been used in treatments for more than 30 years, primarily for cancer. One such treatment famously helped former U.S. President Jimmy Carter beat melanoma.But of the more than 100 monoclonal antibody therapies licensed for use, only seven are for communicable diseases, according to IAVI.Historically, the treatments have been expensive and difficult to produce, but Diomics said it’s targeting a price of about a spray for Dioguard, roughly per bottle.“We do not want to have huge profits from a pandemic, that’s just wrong,” Zolezzi said. “We’re going to price this as effectively as we can for the masses. We want to get this out to the masses.”Animal testing is about to begin and the companies said they hope to progress to human trials soon. Their goal is to release the spray in early 2021, when a vaccine may be on the market but not yet widely available.If the spray works, it could be adapted to other viruses to help fight future pandemics, Zolezzi said."That’s our real goal," Zolezzi said. "That we never get caught flat-footed like this time." 3526

SAN DIEGO (KGTV) -- As Hurricane Maria barrels past Puerto Rico and toward the Dominican Republic, one San Diegan is finally home from a different storm.  167

来源：资阳报